Fennec Pharmaceuticals Azioni (NASDAQ: FENC)

Fennec Pharmaceuticals (NASDAQ:FENC) Azioni

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals Inc

News

Dividends

Buybacks

Synchrony Financial Board Approved Up To $2.5B Share Repurchase Program; Co. Also Raised Quarterly Dividend From $0.25 To $0.30/Share

Equifax Sees Q2 Revenues Between $1.495B-$1.525B (estimate: $1.50B), Adjusted EPS Between $1.85-$1.95 (estimate: $1.89)

Needham analyst Ryan Koontz reiterates Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and maintains $53 price target.

Price Target

Reiteration

Analyst Ratings

CALX

Needham Reiterates Buy on Calix, Maintains $53 Price Target

Tech

General

AKAM

Akamai's New State Of The Internet (SOTI) Report Finds 311B Web Attacks In 2024, A 33% Increase

Low‑income seniors and disabled Americans who rely on Supplemental Security Income (SSI) will see two government deposits in May — one on Wednesday, May 1, and a second on Thursday, May 30. 
What To Know: The back‑to‑back checks are not a windfall. The early payment simply replaces June's benefit because June 1 lands on a Sunday, when Treasury offices are closed.
SSI always pays on the first of the month, but the schedule shifts whenever the 1st falls on a weekend or a federal holiday. In those cases, the money moves up to the business day immediately before, creating a "double‑pay" month followed by a gap month with no deposit.
<h3 class="wp-block-heading">More Calendar Oddities</h3>
That quirk pops up <a href="https://www.ssa.gov/pubs/EN-05-10031-2025.pdf">several more times</a> this year. Beneficiaries will get two payments in August (Aug. 1 and Aug. 29) ahead of Labor Day; in October (Oct. 1 and Oct. 31) because Nov. 1 is a Saturday; and in December (Dec. 1 and Dec. 31) to work around the New Year's Day holiday. Recipients need to budget carefully so the early check lasts through the skipped months — June, September, November, and January 2026, respectively.
See also: <a href="https://www.benzinga.com/personal-finance/25/04/44901238/even-missing-one-monthly-benefit-would-put-me-on-step-to-homelessness-americans-react-to-social-securitys-new-anti-fraud-rules">&#8216;Even Missing One Monthly Benefit Would Put Me On Step To Homelessness&#8217;: Americans React to Social Security&#8217;s New Anti-Fraud Rules</a>
<h3 class="wp-block-heading">What Is Supplemental Security Income Or SSI?</h3>
SSI supports <a href="https://www.benzinga.com/money/ssi-vs-ssd-what-is-the-difference">roughly eight million people</a> who are blind, disabled, or over 65 with limited income. Their payouts are <a href="https://www.benzinga.com/money/will-my-disability-benefits-change-at-retirement-age">separate from retirement</a> and disability checks issued under the larger Social Security program, which follows a birthday‑based schedule: benefits arrive on the second Wednesday for those born 1‑10, the third Wednesday for birthdays 11‑20, and the fourth Wednesday for birthdays 21‑31.
Claimants who began collecting Social Security before May 1997, or who receive both Social Security and SSI, follow a hybrid timetable — Social Security on the 3rd of each month, SSI on the 1st. Regardless of category, the Social Security Administration stresses that payout dates are fixed years in advance; what looks like a bonus is simply the calendar running its course.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read next: <a href="https://www.benzinga.com/general/education/25/04/44894410/dave-ramsey-tells-retirees-dont-count-on-it-or-dont-count-on-all-of-it-why-he-doubts-social-securitys-future">Dave Ramsey Tells Retirees &#8216;Don&#8217;t Count On it, Or Don&#8217;t Count On All Of It&#8217; — Why He Doubts Social Security&#8217;s Future</a>

Personal Finance

Calendar Glitch Brings Two SSI Checks In May — But There's A Catch

Equifax Authorizes New $3B Share Repurchase Program And 28% Dividend Increase To $0.50 Per Share

ITRG

Integra Resources Says Florida Canyon Mine Produced 19,323 Ounces Of Gold And Sold 19,540 Ounces Of Gold In Q1

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and lowers the price target from $15 to $14.

ALMS

HC Wainwright & Co. Maintains Buy on Alumis, Lowers Price Target to $14

On Monday, April 21, U.S. markets closed lower as President Trump intensified his criticism of Federal Reserve Chair Jerome Powell, raising fresh concerns over the central bank&#8217;s independence. Tech stocks led the sell-off, pulling all major indexes into negative territory. Ongoing trade tensions with China weighed on investor sentiment while anticipation built around upcoming corporate earnings reports.
All 11 sectors in the S&amp;P 500 ended the day in the red, with energy, consumer discretionary, and information technology stocks posting the largest losses.
The Dow Jones Industrial Average dropped 2.48% to 38,170.41, the S&amp;P 500 declined 2.36% to 5,158.20, and the Nasdaq Composite fell 2.55% to 15,870.90.
Related: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44909343/speculators-ramp-up-bets-on-who-will-succeed-fed-chair-powell-as-trumps-pressure-campaign-intensifies" rel="noreferrer noopener">Speculators Ramp Up Bets On Who Will Succeed Fed Chair Powell As Trump&#8217;s Pressure Campaign Intensifies</a>
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 0.14% to close at 34,230.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.</li>
<li>Australia&#8217; S&amp;P/ASX 200 closed lower by 0.03% at 7,816.70, led by losses in the IT, Energy and Healthcare sectors.</li>
<li>India&#8217;s Nifty 50 rose 0.18% to 24,170.00 and Nifty 500 rose 0.40% to 22,094.15.</li>
<li>China&#8217;s Shanghai Composite rose 0.25% to 3,299.76, while Shanghai Shenzhen CSI 300 slid 0.02% to 3,783.95.</li>
<li>Hong Kong&#8217;s Hang Seng closed 0.78% higher at 21,562.32.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was down 0.25%.</li>
<li>Germany&#8217;s DAX declined 0.19%.</li>
<li>France&#8217;s CAC 40 fell 0.28%.</li>
<li>U.K.&#8217;s FTSE 100 index traded higher by 0.38%.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 1.07% at $63.48/bbl, and Brent was up 1.57% at $67.30/bbl.</li>
<li>Oil prices rose on Tuesday as traders covered short positions after Monday&#8217;s sharp drop, though concerns lingered over tariffs and U.S. monetary policy dampening fuel demand. Gains were limited by progress in U.S.-Iran nuclear talks, which eased supply fears.</li>
<li>Natural Gas rose 0.70% to $3.037.</li>
<li>Gold was trading higher by 1.24% at $3,46.86, Silver was up 0.13% to $32.563, and Copper rose 0.82% to $4.7670.</li>
<li>Gold prices hit a new record high on Tuesday, driven by safe-haven demand amid U.S.-China trade tensions and concerns over Trump&#8217;s push to overhaul the Federal Reserve.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were up 0.87%, S&amp;P 500 futures gained 0.98% and Nasdaq 100 futures rose 0.99%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index slipped 0.01% to 98.34, USD/JPY was down 0.35% to 140.35, and USD/AUD gained 0.15% to 1.5608.</li>
<li>The dollar fell to new lows Tuesday as Trump&#8217;s criticism of Fed Chair Powell sparked concerns over central bank independence and weakened confidence in the currency.</li>
</ul>
Image Via Shutterstock

Asia

Emerging Markets

Eurozone

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Gold Hits Record High, Dollar Weakens As Trump's Policy Stance And Fed Chair Criticism Induces Uncertainty

Guidance

3M Sees 2025 Adjusted EPS Of $7.60-$7.90 (Vs. Cons. $7.75), And Additional Tariff Sensitivity Of $(0.20) To $(0.40) Per Share

GE Aerospace Full Year 2025 Guidance For 2025,&nbsp;
GE Aerospace is maintaining the following total company and business specific guidance:&nbsp;
2024 2025 Guide Adjusted Revenue&#x2A; Growth Adjusted Revenue&#x2A; '+10% $35.1B LDD Operating Profit&#x2A; Operating profit margin&#x2A; $7.3B 20.7% $7.8 - $8.2B Adjusted EPS&#x2A; $4.60 $5.10 - $5.45 Free Cash Flow&#x2A; FCF&#x2A; conversion-a) $6.1B ~121% $6.3 - $6.8B &gt;100% Commercial Engines &amp; Services (CES): Continue to expect revenue growth in the mid-teens, driven by services growth of low-double-digits to mid-teens, and equipment growth of high-teens. Expect operating profit at $7.6-$7.9 billion. • Defense &amp; Propulsion Technologies (DPT): Continue to expect revenue growth in the mid- to high-singledigit range, and operating profit of $1.1-$1.3 billion. • Corporate: Continue to expect costs to be less than $1 billion.

Earnings

GE Aerospace Sees 2025 EPS Of $5.10–$5.45 Vs. $5.42 Est. And Expects Low Double-Digit Revenue Growth; Outlook Reflects Tariff Impact And Delayed Engine Deliveries

Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.40 by 9.29 percent. This is a 2 percent increase over earnings of $1.50 per share from the same period last year. The company reported quarterly sales of $1.44 billion which beat the analyst consensus estimate of $1.42 billion by 1.55 percent. This is a 3.82 percent increase over sales of $1.39 billion the same period last year.

Earnings Beats

Equifax Q1 Adj EPS $1.53 Beats $1.40 Estimate, Sales $1.44B Beat $1.42B Estimate

PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) reported quarterly earnings of $2.57 per share which beat the analyst consensus estimate of $2.45 by 4.9 percent. This is a 10.45 percent decrease over earnings of $2.87 per share from the same period last year. The company reported quarterly sales of $3.89 billion which beat the analyst consensus estimate of $3.82 billion by 1.85 percent. This is a 1.42 percent decrease over sales of $3.95 billion the same period last year.

PulteGroup Q1 EPS $2.57 Beats $2.45 Estimate, Sales $3.89B Beat $3.82B Estimate

Herc Holdings Sees 2025 Adj. EBITDA Excluding Cinelease $1.575B-$1.650B, Sees Equipment Rental Revenue Growth Excluding Cinelease 4-6%

3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.77 by 6.21 percent. This is a 21.34 percent decrease over earnings of $2.39 per share from the same period last year. The company reported quarterly sales of $5.95 billion which beat the analyst consensus estimate of $5.76 billion by 3.42 percent. This is a 22.90 percent decrease over sales of $7.72 billion the same period last year.

3M Q1 2025 Adj EPS $1.88 Beats $1.77 Estimate, Sales $5.95B Beat $5.76B Estimate

Earnings Misses

Herc Hldgs Q1 2025 Adj. EPS $1.30 May Not Compare To $2.26 Estimate, Sales $861M Beat $849.440M Estimate

Pat Gelsinger, the former CEO of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), expressed admiration for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and its superior performance in the artificial intelligence chip market.
What Happened: Gelsinger praised Nvidia&#8217;s ability in an <a href="https://youtu.be/7fmz9gHDgJU?feature=shared">interview</a> with Yahoo Finance to outperform competitors, attributing its success to two main factors: execution and a competitive advantage in AI products.
Gelsinger, who <a href="https://www.benzinga.com/25/03/44506966/former-intel-boss-pat-gelsinger-says-trumps-tariffs-are-helpful-for-us-chip-comeback-but-it-needs-more-than-tsmcs-100-billion-pledge-reveals-the-one-missing-piece">resigned as Intel&#8217;s CEO in December</a>, praised Nvidia Co-Founder and CEO Jensen Huang for his leadership. He stated, &#8220;They are executing well. At the end of the day, Jensen is on it — driving his teams to stay in the front end.&#8221;
He also acknowledged Nvidia&#8217;s ability to &#8220;run hard to stay in the front&#8221; in the silicon AI accelerator market, a sector experiencing significant growth due to increased spending from large companies and the emergence of AI startups.
See Also: <a href="https://www.benzinga.com/tech/25/04/44890247/openais-codex-cli-intels-reshuffle-and-nvidias-500b-commitment-this-week-in-artificial-intelligence">OpenAI&#8217;s Codex CLI, Intel&#8217;s Reshuffle, And Nvidia&#8217;s $500B Commitment: This Week In Artificial Intelligence</a>
Why It Matters: According to Gelsinger, Nvidia&#8217;s second strength lies in building &#8220;meaningful moats,&#8221; or sustainable advantages that shield the company from competition. He cited Nvidia&#8217;s NVLink and CUDA technologies as examples of these competitive moats.
Gelsinger&#8217;s remarks <a href="https://www.benzinga.com/25/03/44506966/former-intel-boss-pat-gelsinger-says-trumps-tariffs-are-helpful-for-us-chip-comeback-but-it-needs-more-than-tsmcs-100-billion-pledge-reveals-the-one-missing-piece">coincide with Intel&#8217;s struggles</a>, which include a 45% decline in the company&#8217;s share price in the previous year. In his first public appearance as CEO, Lip-Bu Tan, Intel&#8217;s new CEO, recently admitted the company&#8217;s flaws.
Intel outperforms rivals Nvidia and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) on valuation metrics, but Huang-led Nvidia excels in momentum and growth, according to Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Sign up to learn more</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44916245/congress-could-greenlight-trumps-big-beautiful-tax-bill-by-summer-things-are-moving-very-very-quickly-says-hassett">Congress Could Greenlight Trump&#8217;s &#8216;Big Beautiful&#8217; Tax Bill By Summer: &#8216;Things Are Moving Very, Very Quickly,&#8217; Says Hassett</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

INTC

NVDA

Nvidia CEO Jensen Huang Earns Praise From Former Intel CEO Pat Gelsinger: 'Run Hard To Stay In The Front'

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $185 to $168.

NBIX

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $168

As <a href="https://www.benzinga.com/25/04/44915268/nasdaq-dips-over-400-points-amid-plunge-in-tesla-nvidia-shares-investor-fear-eases-but-fear-greed-index-remains-i">U.S. stocks continue to slide</a> in spite of robust corporate earnings, CNBC's Jim Cramer says the <a href="https://www.benzinga.com/25/04/44914873/walgreens-to-pay-up-to-350m-for-illegal-opioid-prescriptions-doj-says">downturn</a> does not have much to do with fundamentals, and everything to do with political and economic chaos.
What Happened: Cramer said on Monday that the sell-off harks back to the 2011 Eurozone crisis, calling it "a very manufactured crisis — something man-made that can be un-made with the stroke of a pen." He observed that solid earnings are being overshadowed by outside factors.
See Also: <a href="https://www.benzinga.com/25/04/44915795/tom-lee-urges-bessent-and-lutnick-to-put-points-on-the-board-for-a-positive-policy-shock-to-the-stock-market">Tom Lee Urges Bessent And Lutnick To &#8216;Put Points On The Board&#8217; For A &#8216;Positive Policy Shock&#8217; To The Stock Market</a>
Why It Matters: With widespread anxiety over tariffs, increasing political pressure on the Fed, and impending debt ceiling battles, investors may disregard earnings entirely. "Earnings won't matter in this environment," Cramer said, warning of possible U.S. credit downgrades akin to 2011.
Unless leaders make efforts to stabilize sentiment, Cramer says markets will keep going downhill. "Long story short, we need to get used to a market that's down every morning because the earnings won't matter in this environment," he said. "It will be the tariffs and the talk about firing <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44910907/top-fed-voices-defend-powell-slam-trumps-attack-on-central-bank-independence">Jay Powell</a> that define this period."
As of Monday's close, the Nasdaq 100 had fallen 19.86% from its record high of 22,222.61. The S&amp;P 500 was down 16.09% from its peak of 6,147.43, while the Dow Jones sat 18.09% below its 52-week high of 45,073.63.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44915727/gold-tops-3500-as-investors-flee-to-safety-mohamed-el-erian-warns-of-global-system-shift-amid-trump-powell-tensions">Gold Tops $3,500 As Investors Flee To Safety: Mohamed El-Erian Warns Of Global System Shift Amid Trump-Powell Tensions</a></li>
</ul>
Photo courtesy: katz / Shutterstock.com

Jim Cramer Calls It A 'Manufactured Crisis' As Markets Plunge Despite Strong Earnings

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

INSM

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Management

Press Releases

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Financing

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Health Care

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Comments

Fennec Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO